Spondyloarthritis & psoriatic arthritis
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses
Authors' conclusion
Deucravacitinib significantly impacted biomarkers associated with Tyk2 signaling pathways of key inflammatory cytokines, including IL-23 and type I interferon, and those related to collagen matrix turnover.
Study context
- Population
- Patients with psoriatic arthritis (PsA) in a phase 2 trial
- Participants
- 203 patients
- Comparison
- Deucravacitinib 6 mg QD or 12 mg QD vs placebo; serum biomarkers vs disease activity and clinical response
Methodological detailsbiomarker study, placebo-controlled, 1:1:1 randomisation
- Biomarker study
- Placebo-controlled
- 1:1:1 randomisation
Primary result
As reported in the abstract
Serum biomarkers: baseline association, pharmacodynamics and prediction of response · week 16
Odds ratio
15.76
High baseline IL-17A vs Low baseline IL-17A
Odds ratio
15.41
High baseline BD-2 vs Low baseline BD-2
- Correlation of IL-17A with PASI at baseline (r)
- 0.4
- Correlation of BD-2 with PASI at baseline (r)
- 0.56
- Correlation of IL-19 with PASI at baseline (r)
- 0.5
- IL-17A, BD-2, IL-19, CXCL9, CXCL10, CRP, MMP-3 and collagen type 4 degradation marker significantly reduced at week 16 vs baseline in deucravacitinib groups
- P < 0.01
Safety
Hematologic variables
- Changes characteristic of JAK inhibition not observed with deucravacitinib
Original publication
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis Rheumatol. Published 1 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →